Renagel: reducing serum phosphorus in haemodialysis patients.
Approximately half of all dialysis patients experience persistent hyperphosphataemia, which causes significant problems. Renagel is a calcium-free, aluminium-free phosphate binder which reduces serum phosphorus in haemodialysis patients by reducing absorption of dietary phosphorus. This article reviews the management of hyperphosphataemia and presents some Renagel clinical trial data.
Burke
S K
SK
GelTex Pharmaceuticals Inc., Waltham, MA 02451, USA.
D002214:Capsules; D002986:Clinical Trials as Topic; D005782:Gels; D006801:Humans; D010710:Phosphates / Q000097:blood*; D011073:Polyamines / Q000494:pharmacology / Q000627:therapeutic use*; D006435:Renal Dialysis; D000069603:Sevelamer
D002214:Capsules; D005782:Gels; D010710:Phosphates; D011073:Polyamines; D000069603:Sevelamer